High-priority and critical pathogens are highly susceptible to Fetroja in vitro1-3

Susceptibility of >46,000 Gram-negative clinical isolates from multiple countries was tested against Fetroja1

In vitro activity does not necessarily correlate with clinical efficacy.

In vitro susceptibility rates of clinical strains from North America and Europe (2020-2023)a
Fetroja
(cefiderocol)		 Ceftazidime/
avibactam		 Ceftolozane/
tazobactam		 Imipenem/
relebactam		 Meropenem/
vaborbactam		 Colistinb
Enterobacterales (Overall) (N=32,051) 99.8% 99.2% 92.8% 93.8% 98.9% 82.5%
Carbapenem-NS (n=791)c 94.6% 69.9% 2.8% 54.7% 56.9% 72.8%
Ceftazidime/avibactam-NS (n=266) 84.6% 0.0% 0.0% 6.4% 17.3% 66.9%
Ceftolozane/tazobactam-NS (n=2320) 96.8% 88.5% 0.0% 83.1% 85.6% 81.4%
Pseudomonas aeruginosa (Overall) (N=9572) 99.8% 96.1% 95.9% 96.5% — 99.6%
Carbapenem-NS (n=1887)c 99.0% 82.1% 82.2% 82.7% — 99.7%
Ceftazidime/avibactam-NS (n=374) 95.7% 0.0% 31.3% 46.0% — 100.0%
Ceftolozane/tazobactam-NS (n=389) 95.1% 33.9% 0.0% 42.9% — 100.0%
Acinetobacter baumannii complex (Overall) (N=3506) 97.6% — — — — 91.3%
Carbapenem-NS (n=1717)c 95.6% — — — — 84.8%
Stenotrophomonas maltophilia (inherently carbapenem-resistant) (N=1781)* 99.3% — — — — —
Swipe table for more
—=No established CLSI breakpoint

Cross-resistance to BL/BLIs, including ceftazidime/avibactam, ceftolozane/tazobactam, and imipenem/relebactam, did not appear to affect susceptibility to Fetroja1

94.8% of Carb-NS P aeruginosa isolates and 87.7% of Carb-NS Enterobacterales isolates expressing MBLs were susceptible to Fetroja1

SENTRY in vitro susceptibility study design

Over 46,000 clinical isolates of Gram-negative pathogens (Enterobacterales, P aeruginosa, A baumannii-calcoaceticus complex, and S maltophilia*) were consecutively collected via the Element Materials Technology laboratory model from hospitalized patients located in North America and Europe from 2020-2023.1,4

BL/BLI=β-lactam/β-lactamase inhibitor; CLSI=Clinical and Laboratory Standards Institute; MBL=Metallo-β-lactamase; NS=non-susceptible.

a
Ratios (%) of susceptible strains were calculated by using the MIC criteria established by the CLSI. Susceptibility testing was performed using the CLSI broth microdilution method. Fetroja was tested in iron-depleted, cation-adjusted Mueller-Hinton broth that was prepared according to CLSI guidelines.4
b
Intermediate breakpoint was used for colistin.4
c
Carbapenem-non-susceptible was defined as non-susceptibility to meropenem (CLSI).1,5
*
The efficacy of Fetroja in treating clinical infections caused by S maltophilia has not been established in adequate and well-controlled clinical trials.

Fetroja demonstrated sustained activity against carbapenem-resistant Gram-negative pathogens over time1,2,6

Minimal changes in Fetroja activity seen since initial approval1,6

In vitro activity does not necessarily correlate with clinical efficacy.

In vitro susceptibility rates of clinical strains from North America and Europe to Fetroja
2019
(SIDERO-WT)d		 2023
(SENTRY)
Enterobacterales (Overall) 99.4%
(n=6093)		 99.6%
(n=7967)
Carbapenem-NSe 93.2%
(n=220)		 92.9%
(n=266)
P aeruginosa (Overall) 99.9%
(n=1487)		 99.8%
(n=2262)
Carbapenem-NSe 99.4%
(n=343)		 98.8%
(n=423)
A baumannii complex (Overall) 97.3%
(n=1041)		 96.9%
(n=1021)
Carbapenem-NSe 95.0%
(n=537)		 93.5%
(n=459)
S maltophilia (inherently carbapenem-resistant)† 100.0%
(n=466)		 100.0%
(n=573)

The SIDERO-WT study was a multi-year, in vitro surveillance study that ended in 2019; the SENTRY surveillance study began in 20201,2

SIDERO-WT in vitro susceptibility study design

Over 40,000 clinical isolates of Gram-negative pathogens (Enterobacterales, P aeruginosa, A baumannii complex, and S maltophilia†) were collected over 5 consecutive years (from November 2014 to December 2019) by the SIDERO-WT surveillance studies conducted in North America and Europe. Gram-negative isolates from patients with intra-abdominal, urinary tract, lower respiratory tract, skin and soft tissue, or bloodstream infections were collected by clinical laboratories and were tested centrally (IHMA Inc., Schaumburg, IL, USA). Fetroja MICs were determined by microbroth dilution using iron-depleted, cation-adjusted Mueller-Hinton broth (ID-CAMHB) as approved by the CLSI subcommittee on antimicrobial susceptibility testing in January 2016.2

d
Ratios (%) of susceptible strains were calculated by using MIC criteria established by the CLSI.2
e
Carbapenem-non-susceptible was defined as non-susceptibility to meropenem (CLSI).1,5
†
The efficacy of Fetroja in treating clinical infections caused by S maltophilia has not been established in adequate and well-controlled clinical trials.

Even carbapenem-non-susceptible pathogens remain susceptible to Fetroja in vitro2